| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2021 ( Subtotal = $785,542 ) |
| | 2021 | 2021 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R42DC017693 | Broad Spectrum Bitter Taste Antagonists Discovery | 001 | 3 | NIH | 5/20/2021 | $20,940 |
| | 2021 | 2021 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R42DC017693 | Broad Spectrum Bitter Taste Antagonists Discovery | 000 | 3 | NIH | 3/30/2021 | $764,602 |
| | 2021 | 2019 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R43AI141819 | STING Inhibitor Discovery for Rare and Common Autoimmune Diseases | 000 | 1 | NIH | 9/27/2021 | $0 |
| | 2021 | 2019 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R44ES028173 | Humanized Kidney Cellular Toxicity Platforms | 001 | 3 | NIH | 9/28/2021 | $0 |
| | 2021 | 2017 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R44ES028173 | Humanized Kidney Cellular Toxicity Platforms | 000 | 1 | NIH | 9/28/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $816,655 ) |
| | 2020 | 2020 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R42DC017693 | Broad Spectrum Bitter Taste Antagonists Discovery | 000 | 2 | NIH | 3/26/2020 | $816,655 |
| | 2020 | 2018 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R41DC017693 | Bitter Human Taste Bud Epithelial Cell Platforms for Bitter Taste Antagonist Discovery | 000 | 1 | NIH | 3/5/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $867,655 ) |
| | 2019 | 2019 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R41DC017693 | Bitter Human Taste Bud Epithelial Cell Platforms for Bitter Taste Antagonist Discovery | 000 | 1 | NIH | 5/9/2019 | $15,428 |
| | 2019 | 2019 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R43AI141819 | STING Inhibitor Discovery for Rare and Common Autoimmune Diseases | 000 | 1 | NIH | 7/23/2019 | $300,000 |
| | 2019 | 2019 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R44ES028173 | Humanized Kidney Cellular Toxicity Platforms | 000 | 3 | NIH | 5/10/2019 | $552,227 |
|
| Issue Date FY: 2018 ( Subtotal = $1,177,719 ) |
| | 2018 | 2018 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R44OD021987 | Genotyped and Single Cyst-derived Human ADPKD Cell Platforms for Industry and Academia | 000 | 3 | NIH | 4/22/2018 | $384,986 |
| | 2018 | 2018 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R44ES028173 | Humanized Kidney Cellular Toxicity Platforms | 000 | 2 | NIH | 5/16/2018 | $521,625 |
| | 2018 | 2018 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R41DC017693 | Bitter Human Taste Bud Epithelial Cell Platforms for Bitter Taste Antagonist Discovery | 000 | 1 | NIH | 8/24/2018 | $271,108 |
| | 2018 | 2016 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R44DK100183 | Adiponectin Secretion Enhancer Synthetic Organic Drug Discovery and Development | 000 | 3 | NIH | 10/30/2017 | $0 |
| | 2018 | 2013 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R43DK100183 | Adipokine Secretion Enhancer Synthetic Organic Drug Discovery in Human Adipocytes | 000 | 1 | NIH | 10/30/2017 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $660,104 ) |
| | 2017 | 2017 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R44OD021987 | Genotyped and Single Cyst-derived Human ADPKD Cell Platforms for Industry and Academia | 001 | 2 | NIH | 5/2/2017 | $453,894 |
| | 2017 | 2017 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R44ES028173 | Humanized Kidney Cellular Toxicity Platforms | 000 | 1 | NIH | 9/22/2017 | $204,369 |
| | 2017 | 2017 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R44ES028173 | Humanized Kidney Cellular Toxicity Platforms | 001 | 1 | NIH | 9/26/2017 | $1,841 |
| | 2017 | 2016 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R44OD021987 | Genotyped and Single Cyst-derived Human ADPKD Cell Platforms for Industry and Academia | 000 | 1 | NIH | 4/26/2017 | $0 |
| | 2017 | 2015 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R44DK098023 | DBM Anti-Proliferative Lead Small Molecules for Polycystic Kidney Disease | 003 | 3 | NIH | 2/27/2017 | $0 |
| | 2017 | 2015 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R44DK098023 | DBM Anti-Proliferative Lead Small Molecules for Polycystic Kidney Disease | 002 | 3 | NIH | 2/27/2017 | $0 |
| | 2017 | 2013 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R44DK098023 | DBM Anti-Proliferative Lead Small Molecules for Polycystic Kidney Disease | 001 | 1 | NIH | 2/27/2017 | $0 |
| | 2017 | 2013 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R44DK098023 | DBM Anti-Proliferative Lead Small Molecules for Polycystic Kidney Disease | 000 | 1 | NIH | 2/27/2017 | $0 |
| | 2017 | 2012 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R44DK084658 | CF Corrector Ligands Discovered on CF Human Airway Cells | 000 | 3 | NIH | 3/9/2017 | $0 |
| | 2017 | 2012 | DISCOVERYBIOMED, INC. | 400 RIVERHILLS BUSINESS PARK STE 435 | BIRMINGHAM | AL | 35242-5040 | SHELBY | USA | R44DK084658 | CF Corrector Ligands Discovered on CF Human Airway Cells | 001 | 3 | NIH | 5/11/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $1,167,475 ) |
| | 2016 | 2016 | DISCOVERYBIOMED INC | 400 RIVERHILLS BUSINESS PARK | BIRMINGHAM | AL | 35242 | SHELBY | USA | R44DK100183 | Adiponectin Secretion Enhancer Synthetic Organic Drug Discovery and Development | 001 | 3 | NIH | 9/2/2016 | $2,000 |
| | 2016 | 2016 | DISCOVERYBIOMED INC | 400 RIVERHILLS BUSINESS PARK | BIRMINGHAM | AL | 35242 | SHELBY | USA | R44OD021987 | Genotyped and Single Cyst-derived Human ADPKD Cell Platforms for Industry and Academia | 000 | 1 | NIH | 3/31/2016 | $366,185 |
| | 2016 | 2016 | DISCOVERYBIOMED INC | 400 RIVERHILLS BUSINESS PARK | BIRMINGHAM | AL | 35242 | SHELBY | USA | R44DK100183 | Adiponectin Secretion Enhancer Synthetic Organic Drug Discovery and Development | 000 | 3 | NIH | 5/4/2016 | $799,290 |
|
| Issue Date FY: 2015 ( Subtotal = $1,443,862 ) |
| | 2015 | 2015 | DISCOVERYBIOMED INC | 400 RIVERHILLS BUSINESS PARK | BIRMINGHAM | AL | 35242 | SHELBY | USA | R44DK098023 | DBM Anti-Proliferative Lead Small Molecules for Polycystic Kidney Disease | 000 | 3 | NIH | 7/2/2015 | $631,732 |
| | 2015 | 2015 | DISCOVERYBIOMED INC | 400 RIVERHILLS BUSINESS PARK | BIRMINGHAM | AL | 35242 | SHELBY | USA | R44DK100183 | Adiponectin Secretion Enhancer Synthetic Organic Drug Discovery and Development | 000 | 2 | NIH | 3/18/2015 | $812,130 |
|
| Issue Date FY: 2014 ( Subtotal = $728,086 ) |
| | 2014 | 2014 | DISCOVERYBIOMED INC | 400 RIVERHILLS BUSINESS PARK | BIRMINGHAM | AL | 35242 | SHELBY | USA | R44DK098023 | DBM Anti-Proliferative Lead Small Molecules for Polycystic Kidney Disease | 000 | 2 | NIH | 7/15/2014 | $503,386 |
| | 2014 | 2014 | DISCOVERYBIOMED INC | 400 RIVERHILLS BUSINESS PARK | BIRMINGHAM | AL | 35242 | SHELBY | USA | R43DK101209 | Chronically Acting CFTR Inhibitor Discovery for Secretory Diarrhea and ADPKD | 000 | 1 | NIH | 5/12/2014 | $224,700 |
|
| Issue Date FY: 2013 ( Subtotal = $661,260 ) |
| | 2013 | 2013 | DISCOVERYBIOMED INC | 1500 FIRST AVENUE NORTH | BIRMINGHAM | AL | 35203 | JEFFERSON | USA | R44DK098023 | DBM Anti-Proliferative Lead Small Molecules for Polycystic Kidney Disease | 000 | 1 | NIH | 6/17/2013 | $436,560 |
| | 2013 | 2013 | DISCOVERYBIOMED INC | 1500 FIRST AVENUE NORTH | BIRMINGHAM | AL | 35203 | JEFFERSON | USA | R43DK100183 | Adipokine Secretion Enhancer Synthetic Organic Drug Discovery in Human Adipocytes | 000 | 1 | NIH | 9/13/2013 | $224,700 |
|
| Issue Date FY: 2012 ( Subtotal = $873,256 ) |
| | 2012 | 2012 | DISCOVERYBIOMED INC | 1500 FIRST AVENUE NORTH | BIRMINGHAM | AL | 35203 | JEFFERSON | USA | R44DK084658 | CF Corrector Ligands Discovered on CF Human Airway Cells | 000 | 3 | NIH | 9/3/2012 | $651,403 |
| | 2012 | 2012 | DISCOVERYBIOMED INC | 1500 FIRST AVENUE NORTH | BIRMINGHAM | AL | 35203 | JEFFERSON | USA | R43AT006670 | HUMAN ADIPOCYTE PLATFORM FOR DISCOVERY OF NOVEL ADIPONECTIN SECRETAGOGUES | 000 | 1 | NIH | 6/27/2012 | $221,853 |
|
| Issue Date FY: 2011 ( Subtotal = $726,158 ) |
| | 2011 | 2011 | DISCOVERYBIOMED INC | 1500 FIRST AVENUE NORTH | BIRMINGHAM | AL | 35203 | JEFFERSON | USA | R44DK084658 | CF Corrector Ligands Discovered on CF Human Airway Cells | 000 | 2 | NIH | 9/9/2011 | $726,158 |
|
| Issue Date FY: 2010 ( Subtotal = $807,493 ) (Continued on the next page) |
| | 2010 | 2010 | DISCOVERY BIOMED LLC | 1500 FIRST AVENUE NORTH | BIRMINGHAM | AL | 35203 | JEFFERSON | USA | R43AR060111 | DISCOVERY OF INHIBITORS OF PTH-WNT SIGNALING SYNERGY IN BONE CELLS | 000 | 1 | NIH | 8/5/2010 | $234,330 |
|
